Abivax S.A.

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 in Phase 3

Quick facts

Phase 3 pipeline

ABX464 · Immunology, Infectious Disease
ABX464 is a small molecule that modulates RNA splicing to promote the production of anti-inflammatory isoforms of proteins involved in immune regulation.

Phase 1 pipeline

ABX196
ABX464 Repeated dose · Immunology
ABX464 is a small molecule antagonist of RARγ
ABX464 Single dose · Infectious Disease
ABX464 is a small molecule that modulates the RNA splicing process to inhibit HIV replication.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Abivax S.A. portfolio CI brief
Abivax S.A. pipeline updates RSS

Frequently asked questions about Abivax S.A.

What is Abivax S.A.'s pipeline?

Abivax S.A. has 1 drugs in Phase 3, 0 in Phase 2, 3 in Phase 1. Late-stage candidates include ABX464.

Sector hub: All tracked pharma companies